Contact this trialFirst, we need to learn more about you.
Glucagon-like peptide agonist
Liraglutide for Type 1 Diabetes
Recruiting2 awardsPhase 3
Buffalo, New York
This trial will test the effect of liraglutide, a long-acting glucagon-like peptide-1 analog, on blood sugar control in adolescents with Type 1 diabetes. Liraglutide is already approved for the treatment of Type 2 diabetes in adults.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.